Latest News
Alzheimer’s Disease Research, a BrightFocus Foundation program, joined over 4,500 scientists, physicians, and industry leaders from 70 countries at the annual International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) in Lisbon, Portugal. Read our key takeaways.
The company behind the first-of-its-kind blood-based screening test for Alzheimer’s disease—rooted in pivotal early BrightFocus support—has received a $15 million investment that will broaden access to the blood test for patients and doctors.
A National Institute on Aging senior investigator breaks down amyloid trials: what went wrong and what must come next.
Immune cells undergo non-inherited genetic changes that are associated with higher Alzheimer’s risk.
Brightfocus supports a groundbreaking $28M investment by the Canadian Institutes of Health Research to bolster early-career health researchers from historically under-recognized groups.
BrightFocus President and CEO Stacy Pagos Haller spoke with WebMD about the latest breakthroughs in macular degeneration research.
A new study asks the question: what if we could reverse the damage caused by Alzheimer’s disease-related proteins like tau? Learn more.
Newly released research portfolios highlight the 276 biomedical research projects funded by BrightFocus Foundation across 16 countries to defeat Alzheimer’s disease, macular degeneration, and glaucoma.
The anti-amyloid therapy will go off the market later this year.
In This Issue:
- Current Research: Could Vision Lost to Glaucoma Be Restored?
- President’s Corner
- A BrightFocus Glaucoma Chat with Dr. Nazlee Zebardast
- First Look at Upcoming Research
- And more!